Kite Archives - Hospital Professional News

April 2, 2026 Chantal Thurlby-Alexander 2 min read

Expanded access to CAR T-cell therapies in Ireland for adults with certain blood cancers

Gilead Sciences and Kite have announced the reimbursement of two CAR T-cell therapies in Ireland for eligible adult patients with certain relapsed or refractory blood cancers.

$Tecartus CAR T therapy becomes first reimbursed option for relapsed or refractory adult ALL in Ireland.$

December 1, 2025 Chantal Thurlby-Alexander 2 min read

First CAR T Therapy for Relapsed or Refractory Adult ALL Now Reimbursed in Ireland

General Health Healthy Ireland Latest News Public Health

Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.